New paradigms in chronic intestinal inflammation and colon cancer: Role of melatonin

Journal of Pineal Research

Volumn 51, Issue 1, 2011, Pages 44-60

  Motilva, Virginia ^a   García Mauriño, Sofía ^a   Talero, Elena ^a   Illanes, Matilde ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

autophagy; chronic inflammation; colitis; colon cancer; inflammatory bowel disease; melatonin; sirtuins

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ACETYLSALICYLIC ACID; ADENOSINE PHOSPHATE; AUTOPHAGY PROTEIN 5; BECLIN 1; BETA CATENIN; CYCLOOXYGENASE 2; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; I KAPPA B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; LIPID; MELATONIN; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; SMALL INTERFERING RNA; SULINDAC; TOLL LIKE RECEPTOR; UNINDEXED DRUG;

ABDOMINAL CRAMP; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AUTOPHAGY; BACTERIAL INFECTION; BEDTIME DOSAGE; BINDING SITE; CALORIC RESTRICTION; CANCER DIAGNOSIS; CANCER RISK; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DAMAGE; CELL INVASION; CELL METABOLISM; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CHRONIC DISEASE; CIRCADIAN RHYTHM; COLON CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DEACETYLATION; DENDRITIC CELL; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPAIR; DNA SYNTHESIS; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; ENTERITIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TRACT; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HIPPOCAMPUS; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LYMPHATIC SYSTEM; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TH17 CELL; TUMOR GROWTH; ULCERATIVE COLITIS; UNFOLDED PROTEIN RESPONSE;

ANIMALS; AUTOPHAGY; CHRONIC DISEASE; COLONIC NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; MELATONIN;

EID: 79960354764     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00915.x     Document Type: Review

References (205)

1. Latella G, Fiocchi C, Caprili R,. News from the '5th International Meeting on Inflammatory Bowel Diseases' CAPRI 2010. J Crohns Colitis 2010; 4: 690-702.
2. Hanauer SB,. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12: S3-S9. (Pubitemid 43068428)
3. Podolsky DK,. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429. (Pubitemid 34851835)
4. Abreu MT,. The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr Gastroenterol Rep 2002; 4: 481-489.
5. Neurath MF, Weigmann B, Finotto S, et al., The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002; 195: 1129-1143. (Pubitemid 34517139)
6. Montgomery SM, Ekbom A,. Epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol 2002; 18: 416-420. (Pubitemid 34665099)
7. Itzkowitz SH,. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35: 553-571. (Pubitemid 44307575)
8. Chapkin RS, Davidson LA, Ly L, Weeks BR, Lupton JR, Mcmurray DN,. Immunomodulatory effects of (n-3) fatty acids: putative link to inflammation and colon cancer. J Nutr 2007; 137: 200S-204S. (Pubitemid 46052881)
9. Sarra M, Monteleone I, Stolfi C, et al., Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis 2010; 16: 1332-1339.
10. Strober W, Fuss IJ,. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767.
11. Stappenbeck TS, Rioux JD, Mizoguchi A, et al., Crohn disease: a current perspective on genetics, autophagy and immunity. Autophagy 2010. [Epub ahead of print].
12. Martin B, Hirota K, Cua DJ, et al., Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009; 31: 321-330.
13. Cario E,. Innate immune signalling at intestinal mucosal surfaces: a fine line between host protection and destruction. Curr Opin Gastroenterol 2008; 24: 725-732.
14. Huang J, Lam GY, Brumell JH,. Autophagy signaling through reactive oxygen species. Antioxid Redox Signal 2011; 14: 2215-2231.
15. Brant SR, Shugart YY,. Inflammatory bowel disease gene hunting by linkage analysis: rationale, methodology, and present status of the field. Inflamm Bowel Dis 2004; 10: 300-311. (Pubitemid 38618262)
16. Hampe J, Franke A, Rosenstiel P, et al., A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39: 207-211. (Pubitemid 46184351)
17. Rioux JD, Xavier RJ, Taylor KD, et al., Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007; 39: 596-604. (Pubitemid 46676115)
18. Zhang S, Zhao X, Zhang D,. Cellular and molecular immunopathogenesis of ulcerative colitis. Cell Mol Immunol 2006; 3: 35-40.
19. Pasare C, Medzhitov R,. Toll-like receptors and acquired immunity. Semin Immunol 2004; 16: 23-26. (Pubitemid 38147430)
20. Haller D,. Intestinal epithelial cell signalling and host- derived negative regulators under chronic inflammation: to be or not to be activated determines the balance towards commensal bacteria. Neurogastroenterol Motil 2006; 18: 184-199.
21. Fritz JH, Girardin SE, Fitting C, et al., Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 2005; 35: 2459-2470. (Pubitemid 41179767)
22. Lala S, Ogura Y, Osborne C, et al., Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003; 125: 47-57. (Pubitemid 36799106)
23. Wullaert A,. Role of NF-kappaB activation in intestinal immune homeostasis. Int J Med Microbiol 2010; 300: 49-56.
24. Hugot JP, Chamaillard M, Zouali H, et al., Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603. (Pubitemid 32531408)
25. Ogura Y, Bonen DK, Inohara N, et al., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606. (Pubitemid 32531409)
26. Travassos LH, Carneiro LA, Ramjeet M, et al., Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11: 55-62.
27. Cooney R, Baker J, Brain O, et al., NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16: 90-97.
28. Sartor RB,. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407. (Pubitemid 44018812)
29. Gutierrez O, Pipaon C, Inohara N, et al., Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 2002; 277: 41701-41705. (Pubitemid 35257477)
30. Pasparakis M,. Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 2009; 9: 778-788.
31. Tergaonkar V,. NFkappaB pathway: a good signaling paradigm and therapeutic target. Int J Biochem Cell Biol 2006; 38: 1647-1653. (Pubitemid 43947652)
32. Wang S, Liu Z, Wang L, et al., NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009; 6: 327-334.
33. Sartor RB, Hoentjen F,. Proinflammatory cytokines and signaling pathways in intestinal innate immune cells. In: Mucosal Immunology, Mestecky J, Moldoveanu Z, Russell ML, eds, Elsevier, Philadelphia, 2005; pp. 681-701.
34. Martin H,. Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. Mutat Res 2009; 669: 1-7.
35. Guri AJ, Mohapatra SK, Horne WT, et al., The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol 2010; 10: 60.
36. Bassaganya-Riera J, Hontecillas R,. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr 2006; 25: 454-465. (Pubitemid 43843028)
37. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al., Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 2004; 127: 777-791. (Pubitemid 39208411)
38. Lewis JD, Lichtenstein GR, Deren JJ, et al., Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008; 134: 688-695. (Pubitemid 351312727)
39. Lee JW, Kim WH, Yeo J, et al., ER stress is implicated in mitochondrial dysfunction-induced apoptosis of pancreatic beta cells. Mol Cells 2010; 30: 545-549.
40. Kaser A, Zeissig S, Blumberg RS,. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573-621.
41. Takemoto K, Miyata S, Takamura H, et al., Mitochondrial TRAP1 regulates the unfolded protein response in the endoplasmic reticulum. Neurochem Int 2011; 58: 880-887.
42. Kaser A, Martínez-Naves E, Blumberg RS,. Endoplasmic reticulum stress: implications for inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2010; 26: 318-326.
43. Back SH, Lee K, Vink E, et al., Cytoplasmic IRE1alpha-mediated XBP1 mRNA splicing in the absence of nuclear processing and endoplasmic reticulum stress. J Biol Chem 2006; 281: 18691-18706. (Pubitemid 44035530)
44. Kaser A, Blumberg RS,. Endoplasmic reticulum stress and intestinal inflammation. Mucosal Immunol 2010; 3: 11-16.
45. Nakamura T, Furuhashi M, Li P, et al., Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010; 140: 338-348.
46. Hinton JM,. Risk of malignant change in ulcerative colitis. Gut 1966; 7: 427-432.
47. Itzkowitz SH, Yio X,. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287: G7-G17. (Pubitemid 38802113)
48. Grenstein AJ,. Cancer in inflammatory bowel disease. Mt Sinai J Med 2000; 67: 227-240.
49. O'connor PM, Lapointe TK, Beck PL, et al., Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1411-1420.
50. Lea MA,. Recently identified and potential targets for colon cancer treatment. Future Oncol 2010; 6: 993-1002.
51. Talero E, Sánchez-Fidalgo S, Villegas I, et al., Role of different inflammatory and tumor biomarkers in the development of ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis 2011; 17: 696-710.
52. Riddle RH, Goldman H, Ransohof DF, et al., Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical application. Human Pathol 1983; 14: 931-968.
53. Pascal RR,. Dysplasia and early carcinoma in inflammatory bowel disease and colorectal carcinomas. Human Pathol 1994; 25: 1160-1171. (Pubitemid 24351499)
54. Bird PR, Good CK,. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 2000; 112-113: 395-402. (Pubitemid 30138150)
55. Cooper HS, Murthy S, Kido K, et al., Dysplasia and cancer in the dextran sulphate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, β-catenin and expression and the role of inflammation. Carcinogenesis 2000; 21: 757-768. (Pubitemid 30214034)
56. TerziÄ J, Grivennikov S, Karin E, et al., Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-2114.
57. Sun Y, Chen J, Rigas B,. Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis 2009; 30: 93-100.
58. Fukata M, Chen A, Klepper A, et al., Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 2006; 131: 862-877. (Pubitemid 44316821)
59. Aggarwal BB, Shishodia S, Sandur SK, et al., Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-1621. (Pubitemid 44666739)
60. Luo JL, Kamata H, Karin M,. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-2632. (Pubitemid 41434385)
61. Richmond A,. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002; 2: 664-674. (Pubitemid 37328724)
62. Bharti AC, Aggarwal BB,. Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemosensitization. Ann N Y Acad Sci 2002; 973: 392-395. (Pubitemid 36125041)
63. Katsman A, Umezawa K, Bonavida B,. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des 2009; 15: 792-808.
64. Salminen A, Lehtonen M, Suuronen T, et al., Terpenoids: natural inhibitors of NF-kappaB signaling with anti-inflammatory and anticancer potential. Cell Mol Life Sci 2008; 65: 2979-2999.
65. Schmidt MV, Brüne B, Von Knethen A,. The nuclear hormone receptor PPARÎ as a therapeutic target in major diseases. Sci World J 2010; 10: 2181-2197.
66. Kaur J, Sanyal SN,. Modulation of inflammatory changes in early stages of colon cancer through activation of PPARgamma by diclofenac. Eur J Cancer Prev 2010; 19: 319-327.
67. Bassaganya-Riera J, Hontecillas R,. Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2010; 13: 569-573.
68. Meira LB, Bugni JM, Green SL, et al., DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008; 118: 2516-2525. (Pubitemid 351949779)
69. Martín MJ, Jiménez MD, Motilva V,. New issues about nitric oxide and its effects on the gastrointestinal tract. Curr Pharm Des 2001; 7: 881-908. (Pubitemid 32624436)
70. Seril DN, Liao J, Yang GY,. Colorectal carcinoma development in inducible nitric oxide synthase-deficient mice with dextran sulfate sodium-induced ulcerative colitis. Mol Carcinog 2007; 46: 341-353. (Pubitemid 46744454)
71. Azad MB, Chen Y, Gibson SB,. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 2009; 11: 777-790.
72. Huett A, Goel G, Xavier RJ,. A systems biology viewpoint on autophagy in health and disease. Curr Opin Gastroenterol 2010; 26: 302-309.
73. Wirawan E, Vande Walle L, Kersse K, et al., Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 2010; 1: e18.
74. Yousefi S, Perozzo R, Schmid I, et al., Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol 2006; 8: 1124-1132. (Pubitemid 44473608)
75. Balaburski GM, Hontz RD, Murphy ME,. p53 and ARF: unexpected players in autophagy. Trends Cell Biol 2010; 20: 363-369.
76. Maiuri MC, Galluzzi L, Morselli E, et al., Autophagy regulation by p53. Curr Opin Cell Biol 2010; 22: 181-185.
77. Tasdemir E, Maiuri MC, Galluzzi L, et al., Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008; 10: 676-687. (Pubitemid 351772933)
78. Scherz-Shouval R, Weidberg H, Gonen C, et al., p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci U S A 2010; 107: 18511-18516.
79. Bauvy C, Gane P, Arico S, et al., Autophagy delays sulindac sulphide-induced apoptosis in the human intestinal colon cancer cell line HT-29. Exp Cell Res 2001; 268: 139-149. (Pubitemid 32744645)
80. Han J, Hou W, Goldstein LA, et al., Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 2008; 283: 19665-19677.
81. Sato K, Tsuchihara S, Fujii M, et al., Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res 2007; 67: 9677-9684. (Pubitemid 47621214)
82. Nishikawa T, Tsuno NH, Okaji Y, et al., Inhibition of autophagy potentiates sulphorane-induced apoptosis in human colon cancer cells. Ann Surg Oncol 2010; 17: 592-602.
83. Li J, Hou N, Faried A, et al., Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer 2010; 46: 1900-1909.
84. Lu SP, Lin SJ,. Regulation of yeast sirtuins by NAD+ metabolism and calorie restriction. Biochim Biophys Acta 2010; 1804: 1567-1575.
85. Zhang T, Kraus WL,. SIRT1-dependent regulation of chromatin and transcription: linking NAD+ metabolism and signalling to the control of cellular functions. Biochim Biophys Acta 2010; 1804: 1666-1675.
86. Dominy JE, Lee Y, Gerhart-Hines Z, et al., Nutrient-dependent regulation of PGC-1α's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5. Biochim Biophys Acta 2010; 1804: 1676-1683.
87. Imai SI,. 'Clocks' in the NAD world: NAD as a metabolic oscillator for the regulation of metabolism and aging. Biochim Biophys Acta 2010; 1804: 1584-1590.
88. Jung-Hynes B, Reiter RJ, Ahmad N,. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 2010; 48: 9-19.
89. Swanson GR, Burgess HJ, Keshavarzian A,. Sleep disturbances and inflammatory bowel disease: a potential trigger for disease flare? Expert Rev Clin Immunol 2011; 7: 29-36.
90. Singh UP, Singh NP, Balwan S, et al., Resveratrol (trans-3,5,4′- trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulphate sodium-induced colitis. J Pharmacol Exp Ther 2009; 332: 829-839.
91. Cui X, Jin Y, Hofseth AB, et al., Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res 2010; 3: 549-559.
92. Hofseth LJ, Singh UP, Singh NP, et al., Taming the beast within: resveratrol suppresses colitis and prevents colon cancer. Aging 2010; 2: 183-184.
93. Yeung F, Hoberg JE, Ramsey CS, et al., Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23: 2369-2380. (Pubitemid 38954844)
94. Ford J, Jiang M, Milner J,. Cancer-specific functions of SIRT1 enables human epithelial cancer cell growth and survival. Cancer Res 2005; 65: 10457-10463. (Pubitemid 41743740)
95. Stünkel W, Peh BK, Tan YC, et al., Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2007; 2: 1360-1368. (Pubitemid 350176266)
96. Nosho K, Shima K, Irahara N, et al., SIRT1 histonedeacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2009; 22: 922-932.
97. Firestein R, Blander G, Michan S, et al., The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008; 3: e2020.
98. Tetsu O, Mccormick F,. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426. (Pubitemid 29180374)
99. Ge X, Jin Q, Zhang F, et al., PCAF acetylates β-catenin and improves its stability. Mol Biol Cell 2009; 20: 419-427.
100. Polakis P,. Wnt signalling and cancer. Genes Dev 2000; 14: 1837-1851.
101. Holloway KR, Calhoun TN, Saxena M, et al., SIRT1 regulates Dishevalled proteins and promotes transient and constitutive Wnt signalling. Proc Natl Acad Sci USA 2010; 107: 9216-9221.
102. Kabra N, Li Z, Chen L, et al., SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009; 284: 18210-18217.
103. Kennedy BK, Steffen KK, Kaeberlein M,. Ruminations on dietary restriction and aging. Cell Mol Life Sci 2007; 64: 1323-1328. (Pubitemid 46889228)
104. Colman RJ, Anderson RM, Johnson ST, et al., Caloric restriction delays disease onset and mortality in Rhesus monkeys. Science 2009; 325: 201-204.
105. Harrison DE, Strong R, Sharp ZD, et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-395.
106. Campisi J, Yaswen P,. Aging and cancer cell biology. Aging Cell 2009; 8: 221-225.
107. Meley D, Bauvy C, Houben-Weerts JHPM, et al., AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem 2006; 281: 34870-34879. (Pubitemid 46036526)
108. Cantõ C, Gerhart-Hines Z, Feige JN, et al., AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458: 1056-1060.
109. Lee IH, Cao L, Mostoslavsky R, et al., A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA 2008; 105: 3374-3379. (Pubitemid 351723560)
110. Morselli E, Maiuri MC, Markaki M, et al., The life span-prolonging effect of sirtuin-1 is mediated by autophagy. Autophagy 2010; 6: 1-3.
111. Bubenik GA,. Thirty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol 2008; 59: 33-51.
112. Tan DX, Manchester LC, Reiter RJ, et al., A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 1998; 253: 614-620. (Pubitemid 29039192)
113. Jou MJ, Peng TI, Hsu LF, et al., Visualization of melatonin's multiple mitochondrial levels of protection against mitochondrial Ca(2+)-mediated permeability transition and beyond in rat brain astrocytes. J Pineal Res 2010; 48: 20-38.
114. Paradies G, Petrosillo G, Paradies V, et al., Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48: 297-310.
115. Lee YD, Kim JY, Lee KH, et al., Melatonin attenuates lipopolysaccharide- induced acute lung inflammation in sleep-deprived mice. J Pineal Res 2009; 46: 53-57.
116. Lahiri S, Singh P, Singh S, et al., Melatonin protects against experimental reflux esophagitis. J Pineal Res 2009; 46: 207-213.
117. Jung KH, Hong SW, Zheng HM, et al., Melatonin ameliorates cerulein-induced pancreatitis by the modulation of nuclear erythroid 2-related factor 2 and nuclear factor-kappaB in rats. J Pineal Res 2010; 48: 239-250.
118. Jaworek J, Brzozowski T, Konturek SJ,. Melatonin as an organoprotector in the stomach and the pancreas. J Pineal Res 2005; 38: 73-83. (Pubitemid 40293231)
119. Radogna F, Diederich M, Ghibelli L,. Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol 2010; 80: 1844-1852.
120. Sánchez-Barcelõ EJ, Mediavilla MD, Tan DX, et al., Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010; 17: 2070-2095.
121. Reiter RJ,. Melatonin: lowering the High Price of Free Radicals. News Physiol Sci 2000; 15: 246-250.
122. Reiter RJ, Paredes SD, Manchester LC, et al., Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
123. Bonnefont-Rousselot D, Collin F,. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology 2010; 278: 55-67.
124. Rosenstein RE, Pandi-Perumal SR, Srinivasan V, et al., Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis. J Pineal Res 2010; 49: 1-13.
125. Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez JJ, et al., Melatonin and circadian biology in human cardiovascular disease. J Pineal Res 2010; 49: 14-22.
126. Pentney PT, Bubenik GA,. Melatonin reduces the severity of dextran-induced colitis in mice. J Pineal Res 1995; 19: 31-39.
127. Ganguly K, Sharma AV, Reiter RJ, Swarnakar S,. Melatonin promotes angiogenesis during protection and healing of indomethacin-induced gastric ulcer: role of matrix metalloproteinase-2. J Pineal Res 2010; 49: 130-140.
128. Cuzzocrea S, Mazzon E, Serraino I, et al., Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 2001; 30: 1-12. (Pubitemid 32056605)
129. Mei Q, Xu JM, Xiang L, et al., Change of nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad Med J 2005; 81: 667-672. (Pubitemid 41498476)
130. Necefli A, TulumoÄlu B, GiriÅ M, et al., The effect of melatonin on TNBS-induced colitis. Dig Dis Sci 2006; 51: 1538-1545. (Pubitemid 44389282)
131. Esposito E, Mazzon E, Riccardi L, et al., Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res 2008; 45: 166-173.
132. Tahan G, Gramignoli R, Marongiu F, et al., Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acid-induced colitis in rats. Dig Dis Sci 2011; 56: 715-720.
133. Cuzzocrea S, Zingarelli B, Gilad E, et al., Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation. Eur J Pharmacol 1998; 342: 67-76. (Pubitemid 28131347)
134. Barlow-Walden LR, Reiter RJ, Abe M, et al., Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995; 26: 497-502.
135. Pablos MI, Agapito MT, Gutierrez R, et al., Melatonin stimulates the activity of the detoxifying enzyme glutathione peroxidase in several tissues of chicks. J Pineal Res 1995; 19: 111-115.
136. Rodriguez C, Mayo JC, Sainz RM, et al., Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9. (Pubitemid 38130283)
137. Nosál'ová V, Zeman M, Cerná S, et al., Protective effect of melatonin in acetic acid induced colitis in rats. J Pineal Res 2007; 42: 364-370. (Pubitemid 46581661)
138. Dong WG, Mei Q, Yu JP, et al., Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol 2003; 9: 1307-1311. (Pubitemid 36805674)
139. Mei Q, Yu JP, Xu JM, et al., Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin 2002; 23: 882-886.
140. Li JH, Yu JP, Yu HG, et al., Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm 2005; 2005: 185-193.
141. Mazzon E, Esposito E, Crisafulli C, et al., Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res 2006; 41: 363-373. (Pubitemid 44498223)
142. Marquez E, Sánchez-Fidalgo S, Calvo JR, et al., Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis. J Pineal Res 2006; 40: 48-55.
143. Motorajan M, Sadeghi K, Reiter RJ, et al., The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem Mol Biol Int 1995; 37: 1063-1070. (Pubitemid 26181750)
144. Chuang JI, Mohan N, Meltz ML, et al., Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol Int 1996; 20: 687-692. (Pubitemid 26402163)
145. Mann S,. Melatonin for ulcerative colitis? Am J Gastroenterol 2003; 98: 232-233.
146. Calvo JR, Guerrero JM, Osuna C, et al., Melatonin triggers Crohn's disease symptoms. J Pineal Res 2002; 32: 277-278. (Pubitemid 34478292)
147. Maldonado MD, Calvo JR,. Melatonin usage in ulcerative colitis: a case report. J Pineal Res 2008; 45: 339-340.
148. Carrillo-Vico A, Guerrero JM, Lardone PJ, et al., A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200. (Pubitemid 41558451)
149. García-Santos G, Antolín I, Herrera F, et al., Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res 2006; 41: 130-135. (Pubitemid 44141747)
150. Martín-Renedo J, Mauriz JL, Jorquera F, et al., Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 2008; 45: 532-540.
151. Cabrera J, Negrín G, Estévez F, et al., Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. J Pineal Res 2010; 49: 45-54.
152. Jung-Hynes B, Huang W, Reiter RJ, et al., Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 2010; 49: 60-68.
153. Padillo FJ, Ruiz-Rabelo JF, Cruz A, et al., Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. J Pineal Res 2010; 49: 264-270.
154. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, et al., Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 2010; 17: 4462-4481.
155. Reiter RJ, Tan DX, Fuentes-Broto L,. Melatonin: a multitasking molecule. Prog Brain Res 2010; 181: 127-151.
156. Miller SC, Pandi-Perumal SR, Esquifino AI, et al., The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Pathol 2006; 87: 81-87.
157. Yang QH, Xu JN, Xu RK, et al., Antiproliferative effects of melatonin on the growth of rat pituitary prolactin-secreting tumor cells in vitro. J Pineal Res 2007; 42: 172-179.
158. Poon AM, Mak AS, Luk HT,. Melatonin and 2[125I]iodomelatonin binding sites in the human colon. Endocr Res 1996; 22: 77-94.
159. Kos-Kudla B, Ostrowska Z, Kozlowski A, et al., Circadian rhythm of melatonin in patients with colorectal carcinoma. Neuro Endocrinol Lett 2002; 23: 239-242. (Pubitemid 34741933)
160. Schernhammer ES, Laden F, Speizer FE, et al., Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 2003; 95: 825-828. (Pubitemid 36798430)
161. Erren TC, Reiter RJ,. A generalized theory of carcinogenesis due to chronodisruption. Neuro Endocrinol Lett 2008; 29: 815-821.
162. Karasek M, Winczyk K, Kunert-Radek J, et al., Antiproliferative effects of melatonin and CGP 52608 on the murine colon 38 adenocarcinoma in vitro and in vivo. Neuro Endocrinol Lett 1998; 19: 71-78. (Pubitemid 28438269)
163. Karasek M, Pawlikowski M,. Antiproliferative effects of melatonin and CGP 52608. Biol Signals Recept 1999; 8: 75-78. (Pubitemid 29132386)
164. García-Navarro A, González-Puga C, Escames G, et al., Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43: 195-205. (Pubitemid 47078925)
165. Rato AG, Pedrero JG, Martinez MA, et al., Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 1999; 13: 857-868.
166. Farriol M, Venereo Y, Orta X, et al., In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000; 20: 21-24. (Pubitemid 30093182)
167. Sainz RM, Mayo JC, Rodriguez C, et al., Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60: 1407-1426. (Pubitemid 36900523)
168. Yu Q, Miller SC, Osmond DG,. Melatonin inhibits apoptosis during early B-cell development in mouse bone marrow. J Pineal Res 2000; 29: 86-93.
169. Das A, Mcdowell M, Pava MJ, et al., The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors. J Pineal Res 2010; 48: 157-169.
170. Leja-Szpak A, Jaworek J, Pierzchalski P, et al., Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010; 49: 248-255.
171. MeÅen-Mucha G, Winczyk K, Pawlikowski M,. Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine Colon 38 cancer. Anticancer Res 1998; 18: 3615-3619. (Pubitemid 28546499)
172. Winczyk K, Pawlikowski M, Karasek M,. Melatonin and RZR/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer. J Pineal Res 2001; 31: 179-182. (Pubitemid 32778168)
173. Winczyk K, Pawlikowski M, Guerrero JM, et al., Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. Tumour Biol 2002; 23: 298-302. (Pubitemid 36302487)
174. Wenzel U, Nickel A, Daniel H,. Melatonin potentiates flavone-induced apoptosis in human colon cancer cells by increasing the level of glycolytic end products. Int J Cancer 2005; 116: 236-242. (Pubitemid 40967260)
175. González-Puga C, García-Navarro A, Escames G, et al., Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. J Pineal Res 2005; 39: 243-250. (Pubitemid 41337804)
176. Anisimov VN, Popovich IG, Zabezhinski MA,. Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2 dimethylhydrazine in rats. Carcinogenesis 1997; 18: 1549-1553. (Pubitemid 28134778)
177. Anisimov VN, Popovich IG, Shtylik AV, et al., Melatonin and colon carcinogenesis. III. Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by 1,2-dimethylhydrazine in rats. Exp Toxicol Pathol 2000; 52: 71-76. (Pubitemid 30176953)
178. Kossoy G, Ben-Hur H, Popovich I, et al., Melatonin and colon carcinogenesis. IV. Effect of melatonin on proliferative activity and expression of apoptosis-related proteins in the spleen of rats exposed to 1,2-dimethylhydrazine. Oncol Rep 2000; 7: 1401-1405.
179. Tanaka T, Yasui Y, Tanaka M, et al., Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 2009; 177: 128-136.
180. Cuervo AM,. Autophagy: in sickness and in health. Trends Cell Biol 2004; 14: 70-77. (Pubitemid 38186640)
181. Yi J, Luo J,. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta 2010; 1804: 1684-1689.
182. Caballero B, Vega-Naredo I, Sierra V, et al., Autophagy upregulation and loss of NF-kappaB in oxidative stress-related immunodeficient SAMP8 mice. Mech Ageing Dev 2009; 130: 722-730.
183. Guo Y, Wang J, Wang Z, et al., Melatonin protects N2a against ischemia/reperfusion injury through autophagy enhancement. J Huazhong Univ Sci Technolog Med Sci 2010; 30: 1-7.
184. Coto-Montes A, Tomas-Zapico C,. Could melatonin unbalance the equilibrium between autophagy and invasive processes? Autophagy 2006; 2: 126-128.
185. Esrefoglu M, Güi M, Ates B, et al., Ultrastructural clues for the protective effect of melatonin against oxidative damage in cerulein-induced pancreatitis J Pineal Res 2006; 40: 92-97.
186. Kimball SR, Abbas A, Jefferson LS,. Melatonin represses oxidative stress-induced activation of the MAP kinase and mTOR signalling pathways in H4IIE hepatoma cells through inhibition of Ras. J Pineal Res 2008; 44: 379-386. (Pubitemid 351545739)
187. Koh PO,. Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway. Neurosci Lett 2008; 444: 74-78.
188. Kongsuphol P, Mukda S, Nopparat C, et al., Melatonin attenuates methamphetamine-induced deactivation of the mammalian target of rapamycin signaling to induce autophagy in SK-N-SH cells. J Pineal Res 2009; 46: 199-206.
189. Nopparat C, Porter JE, Ebadi M, et al., The mechanism for the neuroprotective effect of melatonin against methamphetamine-induced autophagy. J Pineal Res 2010; 49: 382-389.
190. Yoo YM, Jeung EB,. Melatonin suppresses cyclosporine A-induced autophagy in rat pituitary GH3 cells. J Pineal Res 2010; 48: 204-211.
191. Sahar S, Sassone-Corsi P,. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer 2009; 9: 886-896.
192. Wood PA, Yang X, Taber A, et al., Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res 2008; 6: 1786-1793.
193. Jung-Hynes B, Ahmad N,. SIRT1 controls circadian clock circuitry and promotes cell survival: a connection with age-related neoplasms. FASEB J 2009; 23: 2803-2809.
194. Bartsch C, Bartsch H,. Melatonin in cancer patients and in tumor-bearing animals. Adv Exp Med Biol 1999; 467: 247-264.
195. Reiter RJ, Tan DX, Korkmaz A, et al., Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncog 2007; 13: 303-328. (Pubitemid 351655045)
196. Rakhimova O, Paizullaeva ZK, Aleksandrov VB,. Neuroendocrine changes in patients with inflammatory diseases and colonic cancer. Klin Med (Mosk) 2010; 88: 56-60.
197. Stehle JH, Von Gall C, Korf HW,. Melatonin: a clock-output, a clock-input. J Neuroendocrinol 2003; 15: 383-389. (Pubitemid 36395236)
198. Von Gall C, Weaver DR, Moek J, et al., Melatonin plays a crucial role in the regulation of rhythmic clock gene expression in the mouse pars tuberalis. Ann NY Acad Sci 2005; 1040: 508-511. (Pubitemid 40979855)
199. Torres-Farfan C, Rocco V, Monso C, et al., Maternal melatonin effects on clock gene expression in a nonhuman primate fetus. Endocrinology 2006; 147: 4618-4626. (Pubitemid 44402167)
200. Bang JB, Chang HW, Jung HR, et al., Melatonin attenuates clock gene Cryptochrome1, which may aggravates mouse anti-type II collagen antibody-induced arthritis. Rheumatol Int 2010 [Epub ahead of print].
201. Jung-Hynes B, Schmit TL, Reagan-Shaw SR, et al., Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res 2011; 50: 140-149.
202. Chang HM, Wu UI, Lan CT,. Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. J Pineal Res 2009; 47: 211-220.
203. Gutierrez-Cuesta J, Tajes M, Jimenez A, et al., Evaluation of potencial pro-survival pathways regulated by melatonin in a murine senescente model. J Pineal Res 2008; 45: 497-505.
204. Tajes M, Gutierrez-Cuesta J, Ortuño-Sahagun D, et al., Anti-aging properties of melatonin in an in Vitro murine senescente model: involvement of the sirtuin 1 pathway. J Pineal Res 2009; 47: 228-237.
205. Kaeberlein M,. Resveratrol and rapamycin: are they anti-aging drugs? Bioessays 2010; 32: 96-99.